Jianjiao Ni, Radiation oncologist, MD candidate at Peking Union Medical College shared a post by Estela Rodriguez, Associate Director of Community Outreach-Thoracic Oncology at Sylvester Comprehensive Cancer Center on X, adding:
“Glad that this guideline cited the results from our phase 2 trial (the LUNG-SORT study), which supports the potential survival benefit of LCT in EGFR-mutant NSCLC patients with oligo-residual disease after effective third-generation EGFR-TKIs”
Quoting Estela Rodriguez‘s post:
“Off the press ASCO Living Guidelines on Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations, 2026.3.0 | via Journal of Clinical Oncology. A testament to how rapidly lung cancer care is evolving-these are not AI-generated summaries, but updated, evidence-based guidelines with consensus recommendations from an international panel of experts.
Check out updated algorithms for:
- 1L EGFR therapies and sequencing strategies.
- New HER2mut therapies.”
Title: Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0
Authors: Sonam Puri, Natasha B. Leighl, Nofisat Ismaila, Fawzi Abu Rous, Amith Ahluwalia, Krishna Alluri, Ibrahim Hanna Azar, Toby Campbell, Greg Durm, Jill Feldman, Narjust Florez, Janet Freeman-Daily, Naoki Furuya, Shirish Gadgeel, Balazs Halmos, Hidehito Horinouchi, Sara Kuruvilla, Gary R. Macvicar, Narinder Malhotra, Kristen Ashley Marrone, Deebya Raj Mishra, Michael Mullane, Jarushka Naidoo, Dwight H. Owen, Bruna Pellini, Carolyn J. Presley, Angel Qin, Logan Roof, Erin L. Schenk, Lecia Sequist, Navneet Singh, Eric K. Singhi, Jennifer Marie Suga, Ana I. Velazquez, Yubao Wang, Paul Wheatley Price, Joshua E. Reuss, Lyudmila Bazhenova
Read The Full Article
More posts featuring Estela Rodriguez on OncoDaily.